Category:Lipids - Factbites

Category:Lipids - Factbites
Where results make sense
About us | Why use us? | Reviews | PR | Contact us

Topic: Category:Lipids

Note: these results are not from the primary (high quality) database.

	RACGP Drug Use in Pregnancy March - Lipids
		For example, a drug in category B for which there is an absence of human data is not necessarily safer than a drug in category C. It would be inappropriate and misleading to suggest that a drug with B3 data (an animal teratogen) is a 'possible pharmacological hazard' to the human fetus.
		ADEC states that chloroquine used prophylactically is category A, but if used as a treatment for malaria it is category D. The category offered by MIMS does not distinguish between the two uses and the D classification remains.
		The Australian Drug Evaluation Committee's handbook: Medicines in Pregnancy provides a useful background to the risks of prescribing in pregnancy, but it has limitations.[1] This article aims to explore these limitations and assist GPs to go beyond them to ensure the quality use of medicines in pregnancy.
	www.racgp.org.au /document.asp?id=1469 (2467 words)

	eMedicine
		The balance of serum lipids has been clearly shown to have a significant impact on the pathogenesis of atherosclerotic disease.
		Levels of serum lipids are affected both by diet as well as genetic characteristics.
		Get 1.5 hours of free AMA PRA category 1 credit by completing this peer-reviewed online course from eMedicine's Clinical Knowledge Base.
	www.emedicine.com /rc/rc/i1/lipid.htm (676 words)

	Complement Activation-Related Pseudoallergy Caused by Liposomes, Micellar Carriers of Intravenous Drugs, and Radiocontrast Agents - Begell House Inc.
		Such non-IgE-mediated “pseudoallergic” reactions are primarily caused by (1) certain liposomal formulations of intravenous drugs and imaging agents, (2) infusion liquids containing micelle-forming amphiphilic lipids or synthetic block-copolymer emulsifiers, and (3) iodinated radiocontrast media with limited solubility in water.
		There is growing awareness that numerous drug-induced immediate hypersensitivity reactions (HSRs) do not fit in Gell and Coombs’ Type I category of drug allergies, characterized by the pivotal pathogenic role of allergen-specific IgE.
		Common features of the latter “pseudoallergens” include the capacity to activate the complement (C) system; also, the symptoms they cause are often typical manifestations of excessive anaphylatoxin generation in blood.
	www.begellhouse.com /journals/3667c4ae6e8fd136,2dbee23b005233cf,7665cee60b7f8e89.html (676 words)

	hydrolase -- Encyclopædia Britannica
		Esterases include lipases, which break ester bonds (between a carboxylic acid and an alcohol) in lipids, and phosphatases, which act analogously upon phosphates; a narrower category comprises the nucleases, which are phosphatases that hydrolyze nucleic acids.
		Nucleases, which belong to the class of enzymes called hydrolases, are usually specific in action, ribonucleases acting only upon ribonucleic acids (RNA) and deoxyribonucleases acting only upon deoxyribonucleic acids (DNA).
		Lysosomes contain a wide variety of hydrolytic enzymes (acid hydrolases) that break down macromolecules such as...
	www.britannica.com /eb/article-9041737?tocId=9041737 (416 words)

	Lipids Online Slides: hdl, high-density lipoprotein cholesterol
		The treatment effect of fluvastatin on MLD change, calculated as the difference between MLD change in fluvastatin and placebo patients, was significantly greater among low-HDL-C patients than among higher-HDL-C patients (P = 0.01), as assessed by the interaction of treatment and HDL-C category.
		In the Lipoprotein and Coronary Atherosclerosis Study (LCAS), the probability of event-free survival was significantly improved with fluvastatin among patients with low high-density lipoprotein cholesterol (HDL-C) levels (P = 0.002; left panel).
		In the Lipoprotein and Coronary Atherosclerosis Study (LCAS), fluvastatin significantly reduced coronary artery disease progression among patients with low high-density lipoprotein cholesterol (HDL-C), as measured by decreases in minimum lumen diameter (MLD): 0.065 mm versus 0.274 mm with placebo (P = 0.0004).
	www.lipidsonline.org /slides/slide01.cfm?q=hdl&dpg=204 (958 words)

	Lipids Online Slides: hdl, high-density lipoprotein cholesterol
		The treatment effect of fluvastatin on MLD change, calculated as the difference between MLD change in fluvastatin and placebo patients, was significantly greater among low-HDL-C patients than among higher-HDL-C patients (P = 0.01), as assessed by the interaction of treatment and HDL-C category.
		In the Lipoprotein and Coronary Atherosclerosis Study (LCAS), the probability of event-free survival was significantly improved with fluvastatin among patients with low high-density lipoprotein cholesterol (HDL-C) levels (P = 0.002; left panel).
		In the Lipoprotein and Coronary Atherosclerosis Study (LCAS), fluvastatin significantly reduced coronary artery disease progression among patients with low high-density lipoprotein cholesterol (HDL-C), as measured by decreases in minimum lumen diameter (MLD): 0.065 mm versus 0.274 mm with placebo (P = 0.0004).
	www.lipidsonline.org /slides/slide01.cfm?q=hdl&pg=2 (958 words)

	nuclease -- Encyclopædia Britannica
		Esterases include lipases, which break ester bonds (between a carboxylic acid and an alcohol) in lipids, and phosphatases, which act analogously upon phosphates; a narrower category comprises the nucleases, which are phosphatases that hydrolyze nucleic acids.
		Nucleases, which belong to the class of enzymes called hydrolases, are usually specific in action, ribonucleases acting only upon ribonucleic acids (RNA) and deoxyribonucleases acting only upon deoxyribonucleic acids (DNA).
		Some enzymes having a general action (such as phosphoesterases, which hydrolyze phosphoric acid esters) can be...
	www.britannica.com /eb/article-9056452?tocId=9056452 (261 words)

	Lipids Online Slides: niacin, HDL cholesterol, statins, ultrasound
		The third category of medication for consideration in patients with low HDL is niacin.
		Niacin is the most effective HDL-raising drug currently on the market, providing increases in HDL-C in the 25 to 30% range.
		A retrospective analysis of the addition of an extended-release form of niacin to a statin because of persistently low HDL-C suggested that even 1,000 mg of extended-release niacin was associated with an approximately 30% increase in HDL-C, with about a 28% decrease in triglycerides.
	www.lipidsonline.org /slides/slide01.cfm?q=niacin&pg=5 (612 words)

Try your search on: Qwika (all wikis)